Literature DB >> 25201705

Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.

Lecia M Nielsen1,2, Anne E Olesen1, Ruth Branford3, Lona L Christrup2, Hiroe Sato4, Asbjørn M Drewes1,5.   

Abstract

On an individual level, there is a difference in the analgesic response to a given opioid. Various factors such as gender, age, and genetic variation can affect the analgesic response. The genetic variation can influence pharmacokinetics (eg drug transporters and drug-metabolizing enzymes) and/or pharmacodynamics (eg opioid receptor and catechol-O-methyltransferase enzymes). We present recent experimentally induced pain, postoperative pain, and cancer pain and chronic non-malignant pain conditions studies in humans, focusing on the association between genetic variation and analgesic response assessed as opioid consumption or changes in pain scores. Studies have shown promising results regarding pharmacogenetics as a diagnostic tool for predicting the individual response to a given opioid in the experimental settings; however, in the clinic, it is a more complicated task to accomplish.
© 2014 World Institute of Pain.

Entities:  

Keywords:  analgesia; opioids; pharmacodynamics; pharmacogenetics; pharmacokinetics; review; single nucleotide polymorphism

Mesh:

Substances:

Year:  2014        PMID: 25201705     DOI: 10.1111/papr.12232

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  13 in total

Review 1.  Medical Management of Pain in Chronic Pancreatitis.

Authors:  Vikesh K Singh; Asbjørn M Drewes
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

Review 2.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

3.  OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.

Authors:  Kwo Wei David Ho; Margaret R Wallace; Roland Staud; Roger B Fillingim
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.550

4.  Pharmacogenomics of Opioid Treatment for Pain Management.

Authors:  Sarahbeth Howes; Alexandra R Cloutet; Jaeyeon Kweon; Taylor L Powell; Daniel Raza; Elyse M Cornett; Alan D Kaye
Journal:  Methods Mol Biol       Date:  2022

Review 5.  The pharmacogenomics of pain management: prospects for personalized medicine.

Authors:  Sonya Ting; Stephan Schug
Journal:  J Pain Res       Date:  2016-02-10       Impact factor: 3.133

6.  Trends of Opioid Utilisation in Denmark: A Nationwide Study.

Authors:  Søren Kabell Nissen; Anton Pottegård; Jesper Ryg
Journal:  Drugs Real World Outcomes       Date:  2019-12

7.  Drug-target-ADR Network and Possible Implications of Structural Variants in Adverse Events.

Authors:  Bryan Dafniet; Natacha Cerisier; Karine Audouze; Olivier Taboureau
Journal:  Mol Inform       Date:  2020-08-28       Impact factor: 3.353

8.  Reducing Opioid Prescriptions by Identifying Responders on Topical Analgesic Treatment Using an Individualized Medicine and Predictive Analytics Approach.

Authors:  Jeffrey Gudin; Seferina Mavroudi; Aigli Korfiati; Konstantinos Theofilatos; Derek Dietze; Peter Hurwitz
Journal:  J Pain Res       Date:  2020-05-28       Impact factor: 3.133

9.  Prediction of opioid dose in cancer pain patients using genetic profiling: not yet an option with support vector machine learning.

Authors:  Anne Estrup Olesen; Debbie Grønlund; Mikkel Gram; Frank Skorpen; Asbjørn Mohr Drewes; Pål Klepstad
Journal:  BMC Res Notes       Date:  2018-01-27

10.  Impact of CYP3A4*1G Polymorphism on Fentanyl Analgesia Assessed by Analgesia Nociception Index in Chinese Patients Undergoing Hysteroscopy.

Authors:  Qi Yan; Yi Su; Lan Gao; Nan Ding; Hong-Ying Zhang; Wen E; Yue Wang; Yi Feng; Hai-Yan An
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.